勘误：抗CD22和抗CD19嵌合抗原受体T细胞序贯输注治疗1例CART细胞和单倍体造血干细胞移植治疗后复发的儿童Ph样B淋巴细胞白血病患者：病例报告及文献复习[勘误]
Erratum: Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature [Corrigendum].
出版信息
Onco Targets Ther. 2020 Apr 9;13:3045. doi: 10.2147/OTT.S255629. eCollection 2020.
Abstract
[This corrects the article DOI: 10.2147/OTT.S235882.].
摘要
[本文更正了文章DOI：10.2147/OTT.S235882。]
相似文献
1
Erratum: Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature [Corrigendum].勘误：抗CD22和抗CD19嵌合抗原受体T细胞序贯输注治疗1例CART细胞和单倍体造血干细胞移植治疗后复发的儿童Ph样B淋巴细胞白血病患者：病例报告及文献复习[勘误]
Onco Targets Ther. 2020 Apr 9;13:3045. doi: 10.2147/OTT.S255629. eCollection 2020.
2
Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature.抗CD22和抗CD19嵌合抗原受体T细胞序贯输注治疗1例CART细胞和单倍体造血干细胞移植治疗后复发的儿童Ph样B淋巴细胞白血病患者：病例报告及文献复习
Onco Targets Ther. 2020 Mar 17;13:2311-2317. doi: 10.2147/OTT.S235882. eCollection 2020.
3
Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.半相合CD19嵌合抗原受体T细胞与干细胞共同输注在难治性急性淋巴细胞白血病中实现了完全供者植入。
J Hematol Oncol. 2016 Nov 25;9(1):131. doi: 10.1186/s13045-016-0357-z.
4
Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.序贯抗 CD19、22 和 20 自体嵌合抗原受体 T 细胞（CAR-T）治疗复发难治性伯基特淋巴瘤患儿：病例报告及文献复习。
J Cancer Res Clin Oncol. 2020 Jun;146(6):1575-1582. doi: 10.1007/s00432-020-03198-7. Epub 2020 Mar 28.
5
Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.供体来源的靶向CD19的T细胞输注可诱导复发的B细胞急性淋巴细胞白血病患者达到微小残留病阴性缓解，这些患者在单倍体造血干细胞移植后对供体淋巴细胞输注无反应。
Br J Haematol. 2017 Nov;179(4):598-605. doi: 10.1111/bjh.14923. Epub 2017 Oct 26.
6
Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.CD22/CD19 嵌合抗原受体 T 细胞疗法治疗累及胃肠道的复发/难治性侵袭性 B 细胞淋巴瘤患者的疗效和毒性。
Cytotherapy. 2020 Mar;22(3):166-171. doi: 10.1016/j.jcyt.2020.01.008. Epub 2020 Feb 13.
7
[Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].异基因造血干细胞移植后复发的B细胞急性淋巴细胞白血病经CD19嵌合抗原受体T细胞（CAR-T）治疗后的维持治疗
Zhonghua Xue Ye Xue Za Zhi. 2020 Jun 14;41(6):495-501. doi: 10.3760/cma.j.issn.0253-2727.2020.06.011.
8
[Efficacy of CD19 Chimeric Antigen Receptors T Cells in the Treatment of Relapsed Patients with B Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation].CD19嵌合抗原受体T细胞治疗异基因造血干细胞移植后复发的B细胞急性淋巴细胞白血病患者的疗效
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Aug;27(4):1040-1045. doi: 10.19746/j.cnki.issn.1009-2137.2019.04.008.
9
Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation.单倍体相合 CD19/CD22 双特异性 CAR-T 细胞在单倍体相合造血干细胞移植后复发难治性成人 B-ALL 患者中诱导 MRD 阴性缓解。
J Hematol Oncol. 2019 Jun 10;12(1):57. doi: 10.1186/s13045-019-0741-6.
10
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.CD22 靶向 CAR T 细胞可诱导对 CD19 靶向 CAR 免疫疗法初治或耐药的 B-ALL 缓解。
Nat Med. 2018 Jan;24(1):20-28. doi: 10.1038/nm.4441. Epub 2017 Nov 20.
Zotero 插件